-
2023-505249-24-00
5
2021-05-27
HER2-positive metastatic breast cancer
-
2023-503995-26-00
5
2021-05-11
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2023-507890-17-00
5
2021-02-22
Anemia associated with myeloproliferative neoplasm (MPN)-associated my
-
2023-507338-26-00
5
2021-02-01
Histologically documented gastric or gastroesophageal junction adenoca
-
2023-504830-23-00
5
2020-12-16
B-cell Lymphoma
-
2023-504959-27-00
5
2020-12-09
Participants with Limited Stage-Small Cell Lung Cancer, who have recei
-
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
-
2023-506515-18-00
5
2020-10-23
Primary Progressive Multiple Sclerosis (PPMS)
-
2022-502746-27-00
5
2020-08-21
Endometrial Cancer
-
2023-503591-25-00
5
2020-06-09
Non-small cell lung cancer
-
2023-503500-87-00
11
2020-03-17
Muscle Invasive Bladder Cancer
-
2023-505321-14-00
10
2019-09-06
Warm Autoimmune Hemolytic Anemia
-
2023-505810-12-00
5
2019-09-03
Lower limb spasticity
-
2023-509576-42-00
5
2019-02-21
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
-
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C
-
2023-507657-15-00
5
2018-09-13
Ulcerative Colitis
-
2023-509354-58-00
5
2017-07-14
Mantle Cell Lymphoma
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2023-503298-39-00
5
2024-06-13
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
-
2023-507865-24-00
5
2025-03-28
Advanced (unresectable/metastatic) melanoma
-
2024-511557-21-00
5
2024-11-14
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
-
2023-505903-22-00
4
2024-07-02
Sepsis associated acute kidney injury
-
2023-505712-37-00
10
2024-06-06
The participants must have a histologically confirmed diagnosis of res